Latest news with #EES
Yahoo
6 days ago
- Business
- Yahoo
Is WisdomTree U.S. SmallCap ETF (EES) a Strong ETF Right Now?
A smart beta exchange traded fund, the WisdomTree U.S. SmallCap ETF (EES) debuted on 02/23/2007, and offers broad exposure to the Style Box - Small Cap Value category of the market. Market cap weighted indexes were created to reflect the market, or a specific segment of the market, and the ETF industry has traditionally been dominated by products based on this strategy. Market cap weighted indexes offer a low-cost, convenient, and transparent way of replicating market returns, and are a good option for investors who believe in market efficiency. But, there are some investors who would rather invest in smart beta funds; these funds track non-cap weighted strategies, and are a strong option for those who prefer choosing great stocks in order to beat the market. By attempting to pick stocks that have a better chance of risk-return performance, non-cap weighted indexes are based on certain fundamental characteristics, or a combination of such. Even though this space provides many choices to investors--think one of the simplest methodologies like equal-weighting and more complicated ones like fundamental and volatility/momentum based weighting--not all have been able to deliver first-rate results. The fund is managed by Wisdomtree. EES has been able to amass assets over $578.77 million, making it one of the average sized ETFs in the Style Box - Small Cap Value. Before fees and expenses, this particular fund seeks to match the performance of the WisdomTree U.S. SmallCap Earnings Index. The WisdomTree U.S. SmallCap Index is a fundamentally weighted index that measures the performance of earnings-generating companies within the small-capitalization segment of the U.S. Stock Market. Cost is an important factor in selecting the right ETF, and cheaper funds can significantly outperform their more expensive cousins if all other fundamentals are the same. With on par with most peer products in the space, this ETF has annual operating expenses of 0.38%. It's 12-month trailing dividend yield comes in at 1.47%. While ETFs offer diversified exposure, which minimizes single stock risk, a deep look into a fund's holdings is a valuable exercise. And, most ETFs are very transparent products that disclose their holdings on a daily basis. This ETF has heaviest allocation in the Financials sector - about 27.90% of the portfolio. Industrials and Consumer Discretionary round out the top three. Looking at individual holdings, Brighthouse Financial Inc (BHF) accounts for about 1.02% of total assets, followed by Valaris Ltd (G9460G101) and Bgc Group Inc-A (BGC). The top 10 holdings account for about 6.48% of total assets under management. The ETF has lost about -6.70% so far this year and was up about 9.63% in the last one year (as of 06/17/2025). In the past 52-week period, it has traded between $42.54 and $58.78. The ETF has a beta of 1.09 and standard deviation of 22.16% for the trailing three-year period, making it a medium risk choice in the space. With about 911 holdings, it effectively diversifies company-specific risk. WisdomTree U.S. SmallCap ETF is an excellent option for investors seeking to outperform the Style Box - Small Cap Value segment of the market. There are other ETFs in the space which investors could consider as well. IShares Russell 2000 Value ETF (IWN) tracks Russell 2000 Value Index and the Vanguard Small-Cap Value ETF (VBR) tracks CRSP U.S. Small Cap Value Index. IShares Russell 2000 Value ETF has $10.84 billion in assets, Vanguard Small-Cap Value ETF has $28.92 billion. IWN has an expense ratio of 0.24% and VBR charges 0.07%. Investors looking for cheaper and lower-risk options should consider traditional market cap weighted ETFs that aim to match the returns of the Style Box - Small Cap Value. To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report WisdomTree U.S. SmallCap ETF (EES): ETF Research Reports BGC Group, Inc. (BGC) : Free Stock Analysis Report Vanguard Small-Cap Value ETF (VBR): ETF Research Reports iShares Russell 2000 Value ETF (IWN): ETF Research Reports Brighthouse Financial, Inc. (BHF) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Time Business News
14-06-2025
- Time Business News
Caught by a Camera: When Biometrics Replace Visas
VANCOUVER, BC — The sight of a passport being stamped may soon be as nostalgic as flipping through paper maps. As of 2025, dozens of countries have begun phasing out traditional visas and replacing them with biometric entry systems. A camera, not a consular officer, now determines who crosses international borders. With biometric systems—such as face scans, iris recognition, and fingerprints—becoming the global standard, the question for travellers, journalists, and privacy advocates alike is straightforward: What happens when your body becomes your visa? Amicus International Consulting, a global leader in second citizenship programs, identity transformation, and legal relocation, issues this press release to unpack the implications of biometric visas, explore real-world cases, and explain how individuals can still maintain legal mobility and privacy in a world increasingly defined by surveillance. The Rise of the Biometric Visa System Biometric data, which includes facial geometry, fingerprints, iris patterns, and voice profiles, is no longer limited to security agencies or intelligence operations. It now forms the backbone of global travel systems. The replacement of traditional visa procedures with biometric scans is accelerating rapidly. Governments around the world now use biometric systems to: Replace or supplement visa paperwork Confirm identities at e-gates and customs Detect false identities or document forgeries Flag individuals on international watchlists Enforce no-fly lists and cross-border risk assessments The biometric systems are passive, unlike traditional visa processes that require an application; today's systems scan without needing permission or even awareness. Global Leaders in Biometric Border Control As of this year, more than 80 nations have adopted biometric-based entry systems. These include: United States: The Department of Homeland Security's Biometric Entry-Exit Program is active at nearly all international airports. The Department of Homeland Security's Biometric Entry-Exit Program is active at nearly all international airports. European Union: The Entry/Exit System (EES) now scans all non-EU travellers using facial recognition and fingerprints. The Entry/Exit System (EES) now scans all non-EU travellers using facial recognition and fingerprints. China: With its Skynet program, China monitors and records the movement of citizens and foreigners using over 600 million AI-linked cameras. With its Skynet program, China monitors and records the movement of citizens and foreigners using over 600 million AI-linked cameras. United Arab Emirates: Dubai and Abu Dhabi airports utilize biometric e-gates equipped with iris recognition technology. Dubai and Abu Dhabi airports utilize biometric e-gates equipped with iris recognition technology. India: The Aadhaar-linked eVisa system ties biometric identity to mobile numbers and tax records. The Aadhaar-linked eVisa system ties biometric identity to mobile numbers and tax records. South Korea and Singapore: Known for early adoption, these nations now operate fully touchless biometric gates that identify and clear travellers in under ten seconds. Even visa-free nations now require biometric pre-clearance, quietly redefining what it means to be a 'free traveller.' Case Study: The Journalist Flagged by Algorithm In early 2024, a Russian journalist who had previously sought asylum in France attempted to visit Germany using a passport from a Caribbean country acquired through a legal citizenship-by-investment program. At Munich Airport, a biometric gate matched her face to a historic Eurodac asylum database entry. Within minutes, she was detained, questioned, and placed on a return flight—not because her documents were invalid, but because her biometric footprint had been digitally preserved, resurrected, and weaponized. No paper visa was ever denied. No formal notification was issued. Just a camera, a database match, and a door that stayed shut. The Silent Shift: From Application to Algorithm This marks a fundamental shift in global mobility: Old Visa System Application forms Physical interviews Transparent rejections Legal appeals Biometric Visa System Passive enrollment via CCTV or e-gate Invisible watchlists and scoring algorithms Automated denials without explanation Little to no recourse or legal clarity The biometric visa process reverses the burden of proof: travellers must now prove they are not a threat, often without knowing they have been categorized as one. Hidden Triggers: How Biometrics Flag You Facial recognition systems don't just read your face—they interpret behavior, prior travel patterns, and associations. Common biometric triggers include: Re-entry after applying for asylum Previously used aliases, even if legally abandoned Visits to politically controversial countries Association with flagged phone numbers or social media Multiple identities used across jurisdictions Such data is shared through complex networks like PRUM (EU), INTERPOL's facial data program, and the Five Eyes intelligence alliance. Case Study: The Whistleblower Trapped in Transit A Central American cybersecurity contractor exposed evidence of human rights abuses in 2022 and sought safe harbor. He legally obtained a second passport through an investment program in the Caribbean. When flying to Geneva in 2023, the EU's biometric visa system flagged him as a match to a historic INTERPOL Red Notice issued under questionable political grounds. He was held in Zurich airport for 72 hours before being quietly returned to his departure point. His documentation was valid. His face was not. When Biometric Data Goes Wrong Biometric systems are not infallible. Facial recognition algorithms have been criticized for significant error rates, especially among ethnic minorities and women. A 2023 MIT study found that commercial biometric systems had: A 34% higher false-positive rate for Black women compared to white men A 21% error rate for individuals under age 25 due to changing facial features Significant difficulty distinguishing between identical twins or family members One incident in 2024 saw a Dutch student wrongly detained in Turkey due to a false biometric match with a wanted Balkan fugitive. Human Rights Concerns Legal scholars and human rights groups have raised red flags over biometric visa programs: Lack of consent: Biometric collection often occurs without informed permission. Biometric collection often occurs without informed permission. Due process violations: Travelers have no way to appeal or understand denials. Travelers have no way to appeal or understand denials. Surveillance creep: Border technologies are being repurposed for domestic monitoring. Border technologies are being repurposed for domestic monitoring. Chilling effect: Journalists, activists, and dissidents restrict movement out of fear. Journalists, activists, and dissidents restrict movement out of fear. Biometric permanence: Unlike documents, biometrics can't be revoked or reissued. The concern is that biometric systems silently enforce ideological, political, or economic restrictions under the guise of technological efficiency. Amicus International's Biometric Risk Services Amicus International Consulting offers legally compliant solutions for those affected by biometric systems: Second Citizenship Programs: Diversify legal identity options for safer travel Diversify legal identity options for safer travel Facial Recognition Advisory: Evaluate current biometric risks and exposure Evaluate current biometric risks and exposure Secure Relocation Planning: Choose jurisdictions with limited biometric data sharing Choose jurisdictions with limited biometric data sharing Case-Based Identity Strategy: Build documentation to reflect current, lawful identity Build documentation to reflect current, lawful identity Digital Privacy Services: Reduce biometric footprint in global registries Amicus operates exclusively within legal frameworks and does not engage in document forgery or facial spoofing technologies. Case Study: Rebuilding After Biometric Surveillance In 2021, a Middle Eastern human rights advocate living in exile in Malaysia was added to a biometric watchlist following leaked border surveillance documents. Despite holding valid passports, he faced repeated entry refusals. Amicus reviewed his digital trail, prepared a comprehensive dossier of legal name change documentation, and assisted in obtaining a second passport through Grenada's citizenship-by-investment program. Through strategic planning, he relocated to a non-sharing jurisdiction and resumed work under a legal identity with full travel rights. Today, he moves without incident. What the Future Holds By 2026, global travel will look radically different: Over 150 countries will maintain biometric border databases Most eVisas will be auto-issued based on biometric risk scoring Visas may become invisible—issued or denied entirely by algorithm Biometric-only travel corridors will exclude those with privacy concerns or mismatched histories Countries like Estonia, Singapore, and UAE already issue digital 'e-citizenships' tied to biometric blocks on the blockchain—blending identity and surveillance into a single package. Final Thoughts: No Papers, Just Patterns Biometric technology is replacing the passport, the visa, and perhaps even the identity card. The camera is no longer a passive observer—it is the gatekeeper. To travel freely in 2025 and beyond, individuals must understand the systems tracking them, the data fueling decisions, and the legal routes available to reclaim autonomy. Amicus International Consulting remains committed to helping clients navigate this new world—not by dodging the law, but by understanding it better than those who write it. Contact InformationPhone: +1 (604) 200-5402Email: info@ Website:
Korea Herald
13-06-2025
- Health
- Korea Herald
Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels
CLEVELAND, June 13, 2025 /PRNewswire/ -- Primary Investigator, Bernardo Cortese MD, proudly announces the successful completion of patient enrollment in the TRANSFORM II randomized controlled trial (RCT). This pivotal study aims to evaluate the safety and efficacy of the MagicTouch Sirolimus-Coated Balloon (SCB) compared to an everolimus-eluting stent (EES) in treating de-novo coronary vessels. TRANSFORM II (Sirolimus-Coated Balloon Versus Drug-Eluting Stent in Native Coronary Vessels) is an investigator-driven trial sponsored by Fondazione Ricerca e Innovazione Cardiovascolare in Milano, Italy, and has now achieved its target enrollment of >1,820 patients. The final patient was enrolled on 6 th June 2025, marking a major milestone for the trial. Led by Study Chairman Prof. Bernardo Cortese (University Hospitals Harrington Heart & Vascular Institute, Cleveland, USA) and a distinguished steering committee, TRANSFORM II is one of the largest global randomized controlled trials evaluating drug-coated balloon and has enrolled patients from 52 centers across Europe, Asia and South America. Key features of the TRANSFORM II trial include: Prof. Bernardo Cortese, Study Chairman of TRANSFORM II, commented: "After 3 and a half years we were able to complete the enrollment in TRANSFORM II trial, a study that involved 52 centers across 3 continents, and this is amazing. The effort put by our Team in Fondazione RIC and each Investigator of the study led to a quite fast enrollment in such a big, ambitious study. Our goal is to advance the adoption of DCB in the coronary space, testing this sirolimus DCB with the most studied and used DES, in a daily patient population. Along with the guidance of the recently published DCB ARC guidelines, we are paving the route for the modern angioplasty era!". Coronary vessels of this size (which account for roughly 80% of patients undergoing percutaneous coronary interventions) present unique treatment challenges. Currently, interventional cardiologists must often choose a permanent implant namely a drug-eluting stent — effectively "caging" a small vessel — which may compromise long-term outcomes. The head-to-head comparison of MagicTouch SCB against a current standard of care (the EES family of drug-eluting stents) in TRANSFORM II is poised to provide critical evidence for an alternative approach. This trial has the potential to reshape treatment practices by establishing drug-coated balloons as the next viable option for patients with coronary artery disease. Drug-coated balloon technology has long been viewed as a promising solution for small, de-novo coronary lesions, and sirolimus is a viable alternative to the first generation of DCB eluting paclitaxel. Data from this large-scale RCT are expected to support a paradigm shift towards broader use of drug-coated balloons. Implanting a drug-eluting stent in a tiny artery is far from ideal for both patients and physicians, so a rigorous study validating the use of SCB was needed. TRANSFORM II is set to fulfill that need, with initial 12-month outcomes anticipated to shed light on the long-term benefits of avoiding permanent implants in coronary vessels. Dr. Manish Doshi, Founder & Managing Director of Concept Medical Group, commented: "The completion of patient enrollment in TRANSFORM II is a significant milestone in our mission to bring innovative drug-delivery technologies to the forefront of interventional cardiology. We are proud to scientifically support one of the largest global randomized trials evaluating sirolimus-coated balloon technology. This achievement reflects our commitment to clinical excellence, scientific rigor, and ultimately, better outcomes for patients around the world." About MagicTouch SCB The MagicTouch SCB, developed by Concept Medical Inc., utilizes proprietary Nanoluté technology to deliver sub-micron particles of sirolimus encapsulated in a biocompatible carrier, ensuring deep penetration into the vessel wall. The device has received CE Mark approval in Europe alongwith Breakthrough Device Designation & IDE Approval from the U.S. FDA for the treatment of small coronary vessels and in-stent restenosis with ongoing clinical trials. About Concept Medical Inc. Concept Medical Inc., headquartered in Tampa, Florida, has a global presence and is dedicated to enhancing patient care through cutting-edge research and development of drug-delivery technologies. Its proprietary platforms are designed to deliver pharmaceutical agents across vascular luminal surfaces with unparalleled precision. Concept Medical is the developer of the MagicTouch family of Sirolimus-Coated Balloons (SCB) – the world's first and most utilized SCB technology – well recognized for its versatility and efficacy in treating coronary and peripheral artery disease. The revolutionary MagicTouch and Abluminus product lines have been used to treat over a million patients globally, setting a new standard for vascular therapy.
Yahoo
13-06-2025
- Business
- Yahoo
Should WisdomTree U.S. SmallCap ETF (EES) Be on Your Investing Radar?
The WisdomTree U.S. SmallCap ETF (EES) was launched on 02/23/2007, and is a passively managed exchange traded fund designed to offer broad exposure to the Small Cap Value segment of the US equity market. The fund is sponsored by Wisdomtree. It has amassed assets over $583.97 million, making it one of the average sized ETFs attempting to match the Small Cap Value segment of the US equity market. There's a lot of potential to investing in small cap companies, but with market capitalization below $2 billion, that high potential comes with even higher risk. While value stocks have lower than average price-to-earnings and price-to-book ratios, they also have lower than average sales and earnings growth rates. Looking at their long-term performance, value stocks have outperformed growth stocks in almost all markets. They are however likely to underperform growth stocks in strong bull markets. Since cheaper funds tend to produce better results than more expensive funds, assuming all other factors remain equal, it is important for investors to pay attention to an ETF's expense ratio. Annual operating expenses for this ETF are 0.38%, putting it on par with most peer products in the space. It has a 12-month trailing dividend yield of 1.44%. Even though ETFs offer diversified exposure that minimizes single stock risk, investors should also look at the actual holdings inside the fund. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis. This ETF has heaviest allocation to the Financials sector--about 27.90% of the portfolio. Industrials and Consumer Discretionary round out the top three. Looking at individual holdings, Brighthouse Financial Inc (BHF) accounts for about 1.02% of total assets, followed by Valaris Ltd (G9460G101) and Bgc Group Inc-A (BGC). The top 10 holdings account for about 6.48% of total assets under management. EES seeks to match the performance of the WisdomTree U.S. SmallCap Earnings Index before fees and expenses. The WisdomTree U.S. SmallCap Index is a fundamentally weighted index that measures the performance of earnings-generating companies within the small-capitalization segment of the U.S. Stock Market. The ETF has lost about -6.14% so far this year and is up roughly 7.05% in the last one year (as of 06/13/2025). In the past 52-week period, it has traded between $42.54 and $58.78. The ETF has a beta of 1.09 and standard deviation of 22.41% for the trailing three-year period, making it a medium risk choice in the space. With about 911 holdings, it effectively diversifies company-specific risk. WisdomTree U.S. SmallCap ETF holds a Zacks ETF Rank of 2 (Buy), which is based on expected asset class return, expense ratio, and momentum, among other factors. Because of this, EES is an excellent option for investors seeking exposure to the Style Box - Small Cap Value segment of the market. There are other additional ETFs in the space that investors could consider as well. The iShares Russell 2000 Value ETF (IWN) and the Vanguard Small-Cap Value ETF (VBR) track a similar index. While iShares Russell 2000 Value ETF has $11.05 billion in assets, Vanguard Small-Cap Value ETF has $29.07 billion. IWN has an expense ratio of 0.24% and VBR charges 0.07%. Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors. To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report WisdomTree U.S. SmallCap ETF (EES): ETF Research Reports BGC Group, Inc. (BGC) : Free Stock Analysis Report Vanguard Small-Cap Value ETF (VBR): ETF Research Reports iShares Russell 2000 Value ETF (IWN): ETF Research Reports Brighthouse Financial, Inc. (BHF) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Cision Canada
13-06-2025
- Business
- Cision Canada
Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels
CLEVELAND, June 13, 2025 /CNW/ -- Primary Investigator, Bernardo Cortese MD, proudly announces the successful completion of patient enrollment in the TRANSFORM II randomized controlled trial (RCT). This pivotal study aims to evaluate the safety and efficacy of the MagicTouch Sirolimus-Coated Balloon (SCB) compared to an everolimus-eluting stent (EES) in treating de-novo coronary vessels. TRANSFORM II (Sirolimus-Coated Balloon Versus Drug-Eluting Stent in Native Coronary Vessels) is an investigator-driven trial sponsored by Fondazione Ricerca e Innovazione Cardiovascolare in Milano, Italy, and has now achieved its target enrollment of >1,820 patients. The final patient was enrolled on 6 th June 2025, marking a major milestone for the trial. Led by Study Chairman Prof. Bernardo Cortese (University Hospitals Harrington Heart & Vascular Institute, Cleveland, USA) and a distinguished steering committee, TRANSFORM II is one of the largest global randomized controlled trials evaluating drug-coated balloon and has enrolled patients from 52 centers across Europe, Asia and South America. Key features of the TRANSFORM II trial include: Comparative Arms: MagicTouch SCB vs. Everolimus-Eluting Stent (EES) Patient Population: 1,832 patients with de-novo lesions in coronary arteries (vessel diameter >2.0 mm to ≤3.5 mm; lesion length ≤50 mm) Primary Endpoint: Target Lesion Failure at 12 months, non-inferiority design Follow-Up: Patients will be monitored for up to 60 months (5 years) Sub-Study: Optical Coherence Tomography (OCT) imaging in 70 patients at 9 months to assess angiographic outcomes Prof. Bernardo Cortese, Study Chairman of TRANSFORM II, commented: "After 3 and a half years we were able to complete the enrollment in TRANSFORM II trial, a study that involved 52 centers across 3 continents, and this is amazing. The effort put by our Team in Fondazione RIC and each Investigator of the study led to a quite fast enrollment in such a big, ambitious study. Our goal is to advance the adoption of DCB in the coronary space, testing this sirolimus DCB with the most studied and used DES, in a daily patient population. Along with the guidance of the recently published DCB ARC guidelines, we are paving the route for the modern angioplasty era!". Coronary vessels of this size (which account for roughly 80% of patients undergoing percutaneous coronary interventions) present unique treatment challenges. Currently, interventional cardiologists must often choose a permanent implant namely a drug-eluting stent — effectively "caging" a small vessel — which may compromise long-term outcomes. The head-to-head comparison of MagicTouch SCB against a current standard of care (the EES family of drug-eluting stents) in TRANSFORM II is poised to provide critical evidence for an alternative approach. This trial has the potential to reshape treatment practices by establishing drug-coated balloons as the next viable option for patients with coronary artery disease. Drug-coated balloon technology has long been viewed as a promising solution for small, de-novo coronary lesions, and sirolimus is a viable alternative to the first generation of DCB eluting paclitaxel. Data from this large-scale RCT are expected to support a paradigm shift towards broader use of drug-coated balloons. Implanting a drug-eluting stent in a tiny artery is far from ideal for both patients and physicians, so a rigorous study validating the use of SCB was needed. TRANSFORM II is set to fulfill that need, with initial 12-month outcomes anticipated to shed light on the long-term benefits of avoiding permanent implants in coronary vessels. Dr. Manish Doshi, Founder & Managing Director of Concept Medical Group, commented: "The completion of patient enrollment in TRANSFORM II is a significant milestone in our mission to bring innovative drug-delivery technologies to the forefront of interventional cardiology. We are proud to scientifically support one of the largest global randomized trials evaluating sirolimus-coated balloon technology. This achievement reflects our commitment to clinical excellence, scientific rigor, and ultimately, better outcomes for patients around the world." About MagicTouch SCB The MagicTouch SCB, developed by Concept Medical Inc., utilizes proprietary Nanoluté technology to deliver sub-micron particles of sirolimus encapsulated in a biocompatible carrier, ensuring deep penetration into the vessel wall. The device has received CE Mark approval in Europe alongwith Breakthrough Device Designation & IDE Approval from the U.S. FDA for the treatment of small coronary vessels and in-stent restenosis with ongoing clinical trials. About Concept Medical Inc. Concept Medical Inc., headquartered in Tampa, Florida, has a global presence and is dedicated to enhancing patient care through cutting-edge research and development of drug-delivery technologies. Its proprietary platforms are designed to deliver pharmaceutical agents across vascular luminal surfaces with unparalleled precision. Concept Medical is the developer of the MagicTouch family of Sirolimus-Coated Balloons (SCB) – the world's first and most utilized SCB technology – well recognized for its versatility and efficacy in treating coronary and peripheral artery disease. The revolutionary MagicTouch and Abluminus product lines have been used to treat over a million patients globally, setting a new standard for vascular therapy.
